Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

HIV-Fighting Vectored Immunoprophylaxis Antibody Delivery Technique shows Potential

By BiotechDaily International staff writers
Posted on 27 Feb 2014
Print article
Image: The crystal structure of the small virus used to deliver antibodies as vectored immunoprophylaxis (VIP) against HIV (Photo courtesy of Alejandro Balazs, California Institute of Technology).
Image: The crystal structure of the small virus used to deliver antibodies as vectored immunoprophylaxis (VIP) against HIV (Photo courtesy of Alejandro Balazs, California Institute of Technology).
In 2011, US biologists demonstrated a very effective way to deliver HIV-fighting antibodies to laboratory mice: a treatment that protected the mice from infection by a laboratory strain of HIV delivered intravenously. The same researchers have now shown that the procedure is just as effective against a strain of HIV found in the real world, even when transmitted across mucosal surfaces.

The findings, which were published in the February 9, 2014, online publication of the journal Nature Medicine, suggest that the delivery technique might be effective in preventing vaginal transmission of HIV between humans. “The method that we developed has now been validated in the most natural possible setting in a mouse,” stated study leader Nobel Laureate Dr. David Baltimore, president emeritus and a professor of biology at California Institute of Technology (Caltech; Pasadena, USA). “This procedure is extremely effective against a naturally transmitted strain and by an intravaginal infection route, which is a model of how HIV is transmitted in most of the infections that occur in the world.”

The new Caltech delivery technology, called vectored immunoprophylaxis (VIP), is not precisely a vaccine. Vaccines introduce substances such as antigens into the body to try to get the immune system to initiate an appropriate attack, in order to generate antibodies that can stop an infection or T cells that can attack infected cells. In the instance of VIP, a small, harmless virus is injected and delivers genes to the muscle tissue, instructing it to generate specific antibodies.

The researchers emphasized that the research was conducted in lab mice and that human trials are not right around the corner. The team is now working with the vaccine research center at the national institutes of health to begin clinical evaluation.

Related Links:

California Institute of Technology



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.